Ryan D Maynard - Net Worth and Insider Trading

Ryan D Maynard Net Worth

The estimated net worth of Ryan D Maynard is at least $21,642 dollars as of 2025-07-18. Ryan D Maynard is the Director of Iovance Biotherapeutics Inc and owns about 7,500 shares of Iovance Biotherapeutics Inc (IOVA) stock worth over $18,083. Ryan D Maynard is the CHIEF FINANCIAL OFFICER of Cara Therapeutics Inc and owns about 223 shares of Cara Therapeutics Inc (CARA) stock worth over $3,559. Ryan D Maynard is also the EVP & CFO of Rigel Pharmaceuticals Inc and owns about 0 shares of Rigel Pharmaceuticals Inc (RIGL) stock worth over $0. Details can be seen in Ryan D Maynard's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ryan D Maynard has not made any transactions after 2024-11-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of Ryan D Maynard

To

Ryan D Maynard Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ryan D Maynard owns 3 companies in total, including Iovance Biotherapeutics Inc (IOVA) , Rigel Pharmaceuticals Inc (RIGL) , and Cara Therapeutics Inc (CARA) .

Click here to see the complete history of Ryan D Maynard’s form 4 insider trades.

Insider Ownership Summary of Ryan D Maynard

Ticker Company Transaction Date Type of Owner
IOVA Iovance Biotherapeutics Inc 2024-11-12 director
RIGL Rigel Pharmaceuticals Inc 2017-11-03 VP Finance & Acting CFO
CARA Cara Therapeutics Inc 2023-02-08 Chief Financial Officer

Ryan D Maynard Latest Holdings Summary

Ryan D Maynard currently owns a total of 3 stocks. Among these stocks, Ryan D Maynard owns 7,500 shares of Iovance Biotherapeutics Inc (IOVA) as of November 12, 2024, with a value of $18,083 and a weighting of 83.55%. Ryan D Maynard owns 223 shares of Cara Therapeutics Inc (CARA) as of February 8, 2023, with a value of $3,559 and a weighting of 16.45%. Ryan D Maynard also owns 0 shares of Rigel Pharmaceuticals Inc (RIGL) as of November 3, 2017, with a value of $0 and a weighting of 0%.

Latest Holdings of Ryan D Maynard

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IOVA Iovance Biotherapeutics Inc 2024-11-12 7,500 2.41 18,083
CARA Cara Therapeutics Inc 2023-02-08 223 15.96 3,559
RIGL Rigel Pharmaceuticals Inc 2017-11-03 0 18.72 0

Holding Weightings of Ryan D Maynard


Ryan D Maynard Form 4 Trading Tracker

According to the SEC Form 4 filings, Ryan D Maynard has made a total of 2 transactions in Iovance Biotherapeutics Inc (IOVA) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Iovance Biotherapeutics Inc is the sale of 50,000 shares on November 12, 2024, which brought Ryan D Maynard around $503,000.

According to the SEC Form 4 filings, Ryan D Maynard has made a total of 1 transactions in Cara Therapeutics Inc (CARA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Cara Therapeutics Inc is the sale of 152 shares on February 8, 2023, which brought Ryan D Maynard around $2,909.

According to the SEC Form 4 filings, Ryan D Maynard has made a total of 0 transactions in Rigel Pharmaceuticals Inc (RIGL) over the past 5 years. The most-recent trade in Rigel Pharmaceuticals Inc is the sale of 10,000 shares on November 3, 2017, which brought Ryan D Maynard around $390,000.

Insider Trading History of Ryan D Maynard

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ryan D Maynard Trading Performance

GuruFocus tracks the stock performance after each of Ryan D Maynard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ryan D Maynard is 58.81%. GuruFocus also compares Ryan D Maynard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ryan D Maynard within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ryan D Maynard's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ryan D Maynard

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 69.93 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 77.36 LIMIT LIMIT LIMIT LIMIT LIMIT

Ryan D Maynard Ownership Network

Ownership Network List of Ryan D Maynard

No Data

Ownership Network Relation of Ryan D Maynard

Insider Network Chart


Ryan D Maynard Owned Company Details

What does Iovance Biotherapeutics Inc do?

Who are the key executives at Iovance Biotherapeutics Inc?

Ryan D Maynard is the director of Iovance Biotherapeutics Inc. Other key executives at Iovance Biotherapeutics Inc include General Counsel Frederick G Vogt , Chief Operating Officer Igor Bilinsky , and Chief Financial Officer Jean-marc Bellemin .

Iovance Biotherapeutics Inc (IOVA) Insider Trades Summary

Over the past 18 months, Ryan D Maynard made 1 insider transaction in Iovance Biotherapeutics Inc (IOVA) with a net sale of 50,000. Other recent insider transactions involving Iovance Biotherapeutics Inc (IOVA) include a net purchase of 5,000,000 shares made by Wayne P. Rothbaum , a net purchase of 250,000 shares made by Merrill A Mcpeak , and a net purchase of 5,600 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of Iovance Biotherapeutics Inc (IOVA) in total and bought 60,600 shares, with a net purchase of 60,600 shares. During the past 18 months, 50,000 shares of Iovance Biotherapeutics Inc (IOVA) were sold and 5,310,600 shares were bought by its insiders, resulting in a net purchase of 5,260,600 shares.

Iovance Biotherapeutics Inc (IOVA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Iovance Biotherapeutics Inc Insider Transactions

No Available Data

Ryan D Maynard Mailing Address

Above is the net worth, insider trading, and ownership report for Ryan D Maynard. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Ryan D Maynard's mailing address is: South San Francisco Ca 94080.